Advanced in Pemphigus Vulgaris

Dr. David Peace

Oncology
University Of Illinois At Chicago
840 S Wood St, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 3 Trials
Advanced in Pemphigus Vulgaris
University Of Illinois At Chicago
840 S Wood St, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Peace is an Oncologist in Chicago, Illinois. Dr. Peace is rated as an Advanced provider by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

University of Illinois at Chicago
840 S Wood St, Chicago, IL 60612
Other Locations
University of Illinois Hospital
1331 W 75th St, Naperville, IL 60540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: Ruxolitinib, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145
Enrollment Status: Terminated
Publish Date: September 27, 2024
Intervention Type: Drug
Study Drugs: Copanlisib, Nivolumab, Rituximab
Study Phase: Phase 1
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Enrollment Status: Terminated
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 1/Phase 2
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Guadecitabine, Durvalumab
Study Phase: Phase 1/Phase 2
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 19, 2021
Intervention Type: Drug
Study Drugs: Romidepsin, Ixazomib
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

32 Total Publications

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal for immunotherapy of cancer
Published: March 11, 2024
Similar Doctors
Marlon Kleinman
Experienced in Pemphigus Vulgaris
Dr. Marlon Kleinman
Hematology | Oncology
Experienced in Pemphigus Vulgaris
Dr. Marlon Kleinman
Hematology | Oncology

Hematology Oncology Of The North Shore

9631 Gross Point Rd., Suite 10, 
Skokie, IL 
 (13.4 miles away)
847-675-3900
Languages Spoken:
English, Hebrew
See accepted insurances
Offers Telehealth

Marlon Kleinman is a Hematologist and an Oncologist in Skokie, Illinois. Dr. Kleinman is rated as an Advanced provider by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Childhood Iron Deficiency Anemia, Multiple Myeloma, Colorectal Cancer, and Familial Colorectal Cancer.

Rajat Malhotra
Experienced in Pemphigus Vulgaris
Dr. Rajat Malhotra
Hematology | Oncology
Experienced in Pemphigus Vulgaris
Dr. Rajat Malhotra
Hematology | Oncology

Illinois Cancer Specialists

880 W Central Rd, 
Arlington Heights, IL 
 (21.5 miles away)
847-259-4482
Languages Spoken:
English
See accepted insurances

Rajat Malhotra is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Malhotra is rated as a Distinguished provider by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Familial Pancreatic Cancer, Gallbladder Adenocarcinoma, Colorectal Cancer, and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Peace's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile